Search research articles
Contact Us
Filters
Showing results (191-200 of 257) with videos related to
Page
of 26
Sort By:
British Journal of Haematology
|
June 21, 2019
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial
Eileen M Boyle, Xavier Leleu, Marie-Odile Petillon, et al.
Leukemia & Lymphoma
|
July 13, 2017
Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria
Guillemette Fouquet, Kym Ie Snell, Stéphanie Guidez, et al.
Blood
|
January 16, 2013
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02
Xavier Leleu, Michel Attal, Bertrand Arnulf, et al.
The New England Journal of Medicine
|
April 6, 2017
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal, Valerie Lauwers-Cances, Cyrille Hulin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2019
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma
Aurore Perrot, Valérie Lauwers-Cances, Elodie Tournay, et al.
Leukemia
|
August 21, 2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
Thierry Facon, Meletios A Dimopoulos, Nathalie Meuleman, et al.
Leukemia
|
February 27, 2025
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
Thierry Facon, Philippe Moreau, Katja Weisel, et al.
Thrombosis and Haemostasis
|
August 2, 2013
MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs
Xavier Leleu, Philippe Rodon, Cyrille Hulin, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 1, 2023
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies
Gary J Schiller, Brea C Lipe, Nizar J Bahlis, et al.
Leukemia
|
January 2, 2022
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Thierry Facon, Gordon Cook, Saad Z Usmani, et al.
Page
of 26
Search research articles
Search
Showing results (191-200 of 257) with videos related to
Sort By:
Page
of 26
British Journal of Haematology
|
June 21, 2019
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial
Eileen M Boyle, Xavier Leleu, Marie-Odile Petillon, et al.
Leukemia & Lymphoma
|
July 13, 2017
Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria
Guillemette Fouquet, Kym Ie Snell, Stéphanie Guidez, et al.
Blood
|
January 16, 2013
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02
Xavier Leleu, Michel Attal, Bertrand Arnulf, et al.
The New England Journal of Medicine
|
April 6, 2017
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal, Valerie Lauwers-Cances, Cyrille Hulin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2019
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma
Aurore Perrot, Valérie Lauwers-Cances, Elodie Tournay, et al.
Leukemia
|
August 21, 2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
Thierry Facon, Meletios A Dimopoulos, Nathalie Meuleman, et al.
Leukemia
|
February 27, 2025
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
Thierry Facon, Philippe Moreau, Katja Weisel, et al.
Thrombosis and Haemostasis
|
August 2, 2013
MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs
Xavier Leleu, Philippe Rodon, Cyrille Hulin, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 1, 2023
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies
Gary J Schiller, Brea C Lipe, Nizar J Bahlis, et al.
Leukemia
|
January 2, 2022
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Thierry Facon, Gordon Cook, Saad Z Usmani, et al.
Page
of 26